Effects of IAP-EOGBSD on Maternal Vaginal Microbiome, Offspring's Gut Microbiome and Metabolites.
Launched by ZHUJIANG HOSPITAL · Feb 12, 2023
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
This project intends to explore the characteristics of vaginal microbiota of GBS-colonized pregnant women in southern China, the impact of IAP prevention of GBS-EOD on vaginal flora, and the effect of IAP prevention of GBS-EOD on intestinal flora and immune production in offspring, so as to improve the ability to prevent and treat GBS-related diseases in mothers and infants and promote maternal and infant health.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Pregnant women are 18 to 40 years;
- • 35 to 41 weeks of pregnancy;
- • Singleton pregnancy;
- • Plan for vaginal delivery and postpartum care in the research hospital;
- • Pregnant women who volunteered to participate in the study.
- Exclusion Criteria:
- • Have infectious diseases, serious infections and clinical diseases;
- • Use of antibiotics in the past 2 weeks;
- • Long-term use of drugs due to digestion, immunity, blood, chronic diseases;
- • Sexual behavior, vaginal douching and topical medication within 24 hours before sampling;
- • Any medical or non-medical condition that the investigator considers inappropriate to participate.
About Zhujiang Hospital
Zhujiang Hospital, affiliated with the Southern Medical University in Guangzhou, China, is a leading clinical research institution dedicated to advancing medical science and improving patient care through rigorous clinical trials. With a strong commitment to ethical standards and patient safety, the hospital boasts a multidisciplinary team of experienced researchers and healthcare professionals. Its state-of-the-art facilities enable the execution of innovative studies across various therapeutic areas, contributing valuable insights to the global medical community. Zhujiang Hospital aims to foster collaboration with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful development of new therapies and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guang Dong, China
Patients applied
Trial Officials
Qian Wang
Study Chair
Southern Medical University, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials